Zacks Investment Research downgraded Eli Lilly and Co (NYSE:LLY) to Hold in a report released today.
- Updated: October 5, 2016
Yesterday Eli Lilly and Co (NYSE:LLY) traded 0.22% higher at $81.34. The company’s 50-day moving average is $79.28 and its 200-day moving average is $77.34. The last closing price is up 5.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,632,048 shares of the stock traded hands, down from an average trading volume of 3,451,080
Zacks Investment Research has downgraded Eli Lilly and Co (NYSE:LLY) to Hold in a report released on 10/05/2016.
Previously on Tuesday September 27, 2016, Zacks Investment Research reported on Eli Lilly and Co (NYSE:LLY) increased the target price from $0.00 to $89.00. At the time, this indicated a possible upside of 0.12%.
See Chart Below
Eli Lilly and Co has a 52 week low of $67.88 and a 52 week high of $88.16 with a P/E ratio of 35.04 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 21 brokers have issued a research note on the company. The average stock price target is $95.86 with 7 brokers rating the stock a strong buy, 9 brokers rating the stock a buy, 6 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Eli Lilly and Co (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.